Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Date:7/31/2008

CRANBURY, N.J., July 31 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, will announce second quarter 2008 financial results after the regular close of markets on Thursday, August 7, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.

Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-340-7913 (U.S./Canada) or 719-325-4847 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8324472.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and traffic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...blue dye test alternative is helping bring comple...tep closer for pharma-companies. It is a non-destr...ed by Sepha for use with blister packs and it ha...al pharma-companies such as Sanofi-Avenis and Zydu...ivity improvements on the packaging line. Bliste...
(Date:11/25/2009)...swire/ -- Biotech firm Replikins Ltd., which has a... pandemic through the prediction, outbreak, and pr...its latest biochemical analysis of the virus. The ...ine Flu") virus has dropped from its peak of 3.7 (...he spring of 2009 to resting non-epidemic levels t...
(Date:11/25/2009)...wire/ - Cytochroma today announced the appointment.... Moldt will replace Mr. Ulrik Spork as the Novo A...er of Board members remains unchanged at six membe...ldt to the board and look forward to benefiting fr...nues to make progress in becoming a leading CKD-fo...
(Date:11/25/2009)...ire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq:...m.D., president and chief executive officer, will ...re Conference. , ,Presentation details are as fol...rence,Date: Tuesday, December 1, 2009,Time: ... Palace Hotel, New York, NY,Webcast: <a href=,h...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings &#8216;Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings &#8216;Complete Automation' To Pharma-Packaging Quality Assurance 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...ing high purity Type B silica, Tosoh has introduce...e treatment procedures and carbon content levels ,...de range of sample types. , , I... octadecylsilane (ODS) chemistries have been , ...ized properties for select , subsets of c...
... It is well known in HPLC that columns packed wit...at the expense of higher back pressure compared to...The gain in efficiency is usually traded , ...ults in shorter analysis , times and lowe...nes of 5 micron TSK-GEL ODS-100V and ODS-100Z colu...
...public www.dataapex.com , e-mail: vins@dat...V, Bratislava, Slovak Republic, , ...ibution of polymers by the liquid chromatographic ...ectors is a simple, affordable solution for proces...,synthetic and natural polymers. Absolute methods ...
Other Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 3Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 4Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 5
(Date:11/24/2009)...may help gut bacteria bind to the gastrointestinal...ducers to identify strains that are likely to be o...nteract with cells lining the gut to have a benefi... gut they are more likely to stick around long eno...e from the Institute of Food Research. IFR is an ...
(Date:11/24/2009)... -- The Wildlife Conservation Society (WCS) announ...ng population of Siberian tigers has likely declin...g and habitat loss. , WCS says the r...eeds to be done to protect remaining populations o...port was released by the Siberian Tiger Monitoring...
(Date:11/24/2009)..., The presence of increased body fat, and there...he blood, hinders the loss and maintenance of body...versity of Navarra conducted by Estbaliz Goyeneche... The project, entitled "A nutrigenetic and nutrige...ght and inflammation," examines how the individual...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2It can be predicted the reaction obese patients will have to a diet 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 1Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 2Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 3A young brain for an old bee 9076 1A young brain for an old bee 9076 2
...tiple strains of the flu virus, circulating in a p...nes and create a new virus, one capable of infecti...he open-access journal PLoS Biology. This finding ...which viral strains will attack during upcoming fl..., In the first large-scale effort to sequence the ...
...a clever bit of biology called site-specific recom...to another organism, and perform a sort of graftin...into a chromosome of the target cell. The process ...at cause drug resistance or transmit viruses that ...kemias or other cancers. , But what do the surgeon...
... research on a bacterium that can survive encounte...ned scientists, belief that these plentiful white ... our immune system will permit or prevent bacteria...released today online in The Journal of Immunology...ories (RML), part of the National Institute of All...
Other Biology News:Enlisting genomics to understand flu evolution 2Brown-Harvard team solves mobile DNA's surgical sleight-of-hand 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-GPCR G2A Polyclonal Antibody, Unconjugated from Abcam
Anti-6-keto Prostaglandin F1 alpha (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems
Biology Products: